	Item No	Recommendation
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract **[Within the Title Page, page 1 and Method section of the Abstract]**
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found **[See Results Section of the Abstract]**
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported **[See Introduction Section of the Manuscript file, page 2]**
Objectives	3	State specific objectives, including any prespecified hypotheses **[See Introduction Section of the Manuscript file, page 2]**
Methods		
Study design	4	Present key elements of study design early in the paper **[See Methods Section of the Manuscript file, page 2-6]**
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection **[N/A]**
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls **[See Methods Section of the Manuscript file, Pre-treatment Behavioral Appraisal page 4, Post-treatment Behavioral Follow-Up page 5]**
		(*b*) For matched studies, give matching criteria and the number of controls per case **[N/A]**
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable **[See Methods Section of the Manuscript file, Pre-treatment Behavioral Appraisal page 4, Post-treatment Behavioral Follow-Up page 5]**
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group **[N/A]**
Bias	9	Describe any efforts to address potential sources of bias **[See Discussion Section of the Manuscript file, page 8]**
Study size	10	Explain how the study size was arrived at **[Need for reduction to a minimum as possible (20 rats) the number of animal employed for ethical purposes, 3R rules: Reduction, Refinement, Replacement]**
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why **[N/A]**
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding **[See Method Section of the Manuscript file, Statistical Analysis, page 7]**
		(*b*) Describe any methods used to examine subgroups and interactions **[N/A]**
		(*c*) Explain how missing data were addressed **[N/A]**
		(*d*) If applicable, explain how matching of cases and controls was addressed **[N/A]**
		(*e*) Describe any sensitivity analyses **[N/A]**
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed **[See Methods Section of the Manuscript file, Pre-treatment Behavioral Appraisal page 4]**
		(b) Give reasons for non-participation at each stage **[N/A]**
		(c) Consider use of a flow diagram **[See Fig. 1]**
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders **[See Methods Section of the Manuscript file, Pre-treatment Behavioral Appraisal page 4]**
		(b) Indicate number of participants with missing data for each variable of interest **[N/A]**
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included **[See Method Section of the Manuscript file, Statistical Analysis, page 7]**
		(*b*) Report category boundaries when continuous variables were categorized **[N/A]**
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period **[N/A]**
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses **[N/A]**
Discussion		
Key results	18	Summarise key results with reference to study objectives **[See Discussion Section of the Manuscript file, page 8-9]**
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias **[See Discussion Section of the Manuscript file, page 8-9]**
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence **[See Discussion Section of the Manuscript file, page 8-9]**
Generalisability	21	Discuss the generalisability (external validity) of the study results **[See Discussion Section of the Manuscript file, page 8-9]**
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based **[N/A]**

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Supplemental Digital Content 1: STROBE Statement—Checklist of items that should be included in reports of *case-control studies*